Harvard Bioscience Stock Fundamentals
| HBIO Stock | USD 2.24 0.03 1.32% |
Harvard Bioscience fundamentals help investors to digest information that contributes to Harvard Bioscience's financial success or failures. It also enables traders to predict the movement of Harvard Stock. The fundamental analysis module provides a way to measure Harvard Bioscience's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Harvard Bioscience stock.
At this time, Harvard Bioscience's Interest Income is very stable compared to the past year. As of the 26th of November 2024, Reconciled Depreciation is likely to grow to about 7.8 M, while Depreciation And Amortization is likely to drop about 4.3 M. Harvard | Select Account or Indicator |
Harvard Bioscience Company Profit Margin Analysis
Harvard Bioscience's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Harvard Bioscience Profit Margin | (0.15) % |
Most of Harvard Bioscience's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Harvard Bioscience is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Harvard Pretax Profit Margin
Pretax Profit Margin |
|
Based on the latest financial disclosure, Harvard Bioscience has a Profit Margin of -0.1457%. This is 98.7% lower than that of the Life Sciences Tools & Services sector and 99.19% lower than that of the Health Care industry. The profit margin for all United States stocks is 88.53% lower than that of the firm.
Harvard Bioscience Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Harvard Bioscience's current stock value. Our valuation model uses many indicators to compare Harvard Bioscience value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Harvard Bioscience competition to find correlations between indicators driving Harvard Bioscience's intrinsic value. More Info.Harvard Bioscience is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Harvard Bioscience's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Harvard Bioscience's earnings, one of the primary drivers of an investment's value.Harvard Bioscience's Earnings Breakdown by Geography
Harvard Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Harvard Bioscience's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Harvard Bioscience could also be used in its relative valuation, which is a method of valuing Harvard Bioscience by comparing valuation metrics of similar companies.Harvard Bioscience is currently under evaluation in profit margin category among its peers.
Harvard Bioscience ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Harvard Bioscience's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Harvard Bioscience's managers, analysts, and investors.Environmental | Governance | Social |
Harvard Fundamentals
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.0198 | ||||
| Profit Margin | (0.15) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 140.13 M | ||||
| Shares Outstanding | 43.62 M | ||||
| Shares Owned By Insiders | 7.77 % | ||||
| Shares Owned By Institutions | 73.88 % | ||||
| Number Of Shares Shorted | 398.85 K | ||||
| Price To Earning | (25.00) X | ||||
| Price To Book | 1.52 X | ||||
| Price To Sales | 1.01 X | ||||
| Revenue | 112.25 M | ||||
| Gross Profit | 62.29 M | ||||
| EBITDA | 9.49 M | ||||
| Net Income | (3.42 M) | ||||
| Cash And Equivalents | 4.26 M | ||||
| Cash Per Share | 0.10 X | ||||
| Total Debt | 42.77 M | ||||
| Debt To Equity | 0.73 % | ||||
| Current Ratio | 2.42 X | ||||
| Book Value Per Share | 1.50 X | ||||
| Cash Flow From Operations | 14.03 M | ||||
| Short Ratio | 3.22 X | ||||
| Earnings Per Share | (0.33) X | ||||
| Price To Earnings To Growth | 2.89 X | ||||
| Target Price | 6.25 | ||||
| Number Of Employees | 391 | ||||
| Beta | 1.31 | ||||
| Market Capitalization | 99.01 M | ||||
| Total Asset | 137.37 M | ||||
| Retained Earnings | (145.6 M) | ||||
| Working Capital | 22.5 M | ||||
| Current Asset | 50.55 M | ||||
| Current Liabilities | 19.32 M | ||||
| Net Asset | 137.37 M |
About Harvard Bioscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Harvard Bioscience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Harvard Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Harvard Bioscience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 7.7 M | 8.1 M | |
| Total Revenue | 112.2 M | 96.8 M | |
| Cost Of Revenue | 51.4 M | 48.6 M | |
| Stock Based Compensation To Revenue | 0.04 | 0.04 | |
| Sales General And Administrative To Revenue | 0.20 | 0.25 | |
| Research And Ddevelopement To Revenue | 0.10 | 0.11 | |
| Capex To Revenue | 0.02 | 0.02 | |
| Revenue Per Share | 2.65 | 2.42 | |
| Ebit Per Revenue | 0.02 | 0.03 |
Check out Harvard Bioscience Piotroski F Score and Harvard Bioscience Altman Z Score analysis. To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harvard Bioscience. If investors know Harvard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harvard Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share (0.33) | Revenue Per Share 2.258 | Quarterly Revenue Growth (0.13) | Return On Assets (0.02) |
The market value of Harvard Bioscience is measured differently than its book value, which is the value of Harvard that is recorded on the company's balance sheet. Investors also form their own opinion of Harvard Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Harvard Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harvard Bioscience's market value can be influenced by many factors that don't directly affect Harvard Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harvard Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harvard Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harvard Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.